Magnolia Medical Technologies, Inc.

Magnolia Medical Technologies, Inc. is a privately held medical device company headquartered in Seattle, Washington, founded in 2006. The company focuses on developing innovative solutions to improve the accuracy of diagnostic blood culture tests, particularly for sepsis. It has an estimated employee count ranging from 73 to 163, and its annual revenue is estimated to be between $10 million and $51.1 million. Magnolia Medical Technologies has raised over $125 million in funding from various investors.

The company's primary offering is the SteriPath® Initial Specimen Diversion Device® platform, including SteriPath and SteriPath Micro. These systems are pre-assembled, sterile blood collection devices designed to divert and sequester the initial blood flow, which is known to contain contaminants, thereby reducing false-positive blood culture results. The SteriPath platform is FDA 510(k)-cleared with a specific indication to reduce blood culture contamination for sepsis testing accuracy and is supported by clinical evidence. Magnolia Medical Technologies holds a substantial intellectual property portfolio with over 200 issued patents and more than 50 pending applications related to its technologies.

Magnolia Medical Technologies operates as an active operating company defending its intellectual property. The company's patent litigation posture is that of an operating company asserting its patents. As per the provided case data, Magnolia Medical Technologies has one tracked case as a plaintiff and zero as a defendant, indicating it actively enforces its patent rights.

A notable aspect of their litigation is In re Magnolia Medical Technologies, Inc., which involved an appeal to the U.S. Court of Appeals for the Federal Circuit. This case originated from a suit filed against Kurin, Inc. in the District of Delaware, where Magnolia Medical Technologies asserted infringement of its U.S. Patents 10,039,483 and 9,855,001, both related to blood sequestration devices for reducing contamination during blood collection. While a jury initially found infringement of the '483 patent, the district court later granted a judgment of no infringement, which was affirmed by the Federal Circuit. The Federal Circuit also affirmed a Patent Trial and Appeal Board decision finding claim 1 of the '483 patent unpatentable as anticipated in a separate proceeding.